A  C 2 200- "D  E ~-~ 180-  O 130  160-  bq  v  = 140-  bq  .j 120  2 -D  E v  L3 r~  bq  G" bq  v  r-  r~ 03  bq  .J 140-  120  2 -D  E v  L3 r~  bq  G"  r-  r~ 03  bq  .J "0- Baseline  -II- End point  *f  *f  I I I I I I  Exenaude 5 IJg (n = 66)  Figure 4. 200 -  180-  160-  T  t§ t§ Clinical Therapeutics  I I I I I I  Exenaude 10 IJg (n = 67)  200 -  180-  160-  140-  120 I I I I I  Morning Morning Midday Midday Evening Evening  preprandial postprandial preprandial postprandial preprandial postprandial  Placebo (n = 72)  Six-point self-monitored blood glucose (SMBG) values before and after 24-week administration of  exenatide 5 and 10 pg and placebo in patients with type 2 diabetes. *P _< 0.004 versus baseline;  tp < 0.028 versus placebo; ~P < 0.030 versus baseline; §P < 0.015 versus placebo; lip < 0.040 versus  baseline. LS = least squares.  1456 Volume 30 Number 8